A gene-targeting pill for women may provide a highly effective treatment for up to a third of men with advanced prostate cancer, trial results have shown.
Olaparib, the first marketed drug to tackle inherited cancer mutations, was licensed last year for women with ovarian cancer who have faulty BRCA genes.
The new trial, described as a "milestone" by the Institute of Cancer Research, found it could also halt tumour growth in many men with treatment-resistant prostate cancer.
Of the 49 men taking part, a third responded to the drug. Cancers stopped growing, numbers of circulating tumour cells in the blood fell, and clinically positive results were obtained from scans.
Levels of PSA - the blood marker used to track the progress of prostate cancer - also plunged by up to 96%.
Chief investigator Professor Johann de Bono, from the Institute of Cancer Research in London, said: "Our trial marks a significant step forward in the treatment of prostate cancer, showing that olaparib is highly effective at treating men with DNA repair defects in their tumours.
"It also proves the principle that we can detect prostate cancers with specific targetable mutations using genomic sequencing to deliver more precise cancer care by matching treatment to those men most likely to benefit.
"I hope it won't be long before we are using olaparib in the clinic to treat prostate cancer, or before genomic stratification of cancers becomes a standard in this and other cancers."
Sixteen patients had detectable faults in genes that play a role in repairing damaged DNA, including BRCA 1 and 2. Of these, 14 responded very well to olaparib.
A second stage of the trial is now planned which will only recruit men with prostate cancer who have similar detectable gene defects.
If this study also yields positive results, olaparib could become a new treatment option for men with genetically-driven advanced prostate cancer, say the researchers.
However it remains to be seen whether men will qualify for the drug on the NHS due to its high cost. The drug has a list price of £4,740 per month, according to NHS England.
Currently olaparib is not approved for use on the NHS by the National Institute for Health and Care Excellence (Nice) or the Cancer Drugs Fund. Nice is still in the process of considering whether to recommend the drug for women with ovarian cancer.
Health news in pictures
Health news in pictures
1/19 Vaping backed as healthier nicotine alternative to cigarettes after latest study
Vaping has been given an emphatic thumbs up by health experts after the first long-term study of its effects in ex-smokers. After six months, people who switched from real to e-cigarettes had far fewer toxins and cancer-causing substances in their bodies than continual smokers, scientists found
2/19 Common method of cooking rice can leave traces of arsenic in food, scientists warn
Millions of people are putting themselves at risk by cooking their rice incorrectly, scientists have warned. Recent experiments show a common method of cooking rice — simply boiling it in a pan until the water has steamed out — can expose those who eat it to traces of the poison arsenic, which contaminates rice while it is growing as a result of industrial toxins and pesticides
3/19 Contraceptive gel that creates ‘reversible vasectomy’ shown to be effective in monkeys
An injectable contraceptive gel that acts as a ‘reversible vasectomy’ is a step closer to being offered to men following successful trials on monkeys. Vasalgel is injected into the vas deferens, the small duct between the testicles and the urethra. It has so far been found to prevent 100 per cent of conceptions
4/19 Shift work and heavy lifting may reduce women’s fertility, study finds
Women who work at night or do irregular shifts may experience a decline in fertility, a new study has found. Shift and night workers had fewer eggs capable of developing into healthy embryos than those who work regular daytime hours, according to researchers at Harvard University
5/19 Breakfast cereals targeted at children contain 'steadily high' sugar levels since 1992 despite producer claims
A major pressure group has issued a fresh warning about perilously high amounts of sugar in breakfast cereals, specifically those designed for children, and has said that levels have barely been cut at all in the last two and a half decades
6/19 Fight against pancreatic cancer takes ‘monumental leap forward’
Scientists have made a “monumental leap forward” in the treatment of pancreatic cancer after discovering using two drugs together dramatically improved patients’ chances of living more than five years after diagnosis.
7/19 Japanese government tells people to stop overworking
The Japanese government has announced measures to limit the amount of overtime employees can do – in an attempt to stop people literally working themselves to death. A fifth of Japan’s workforce are at risk of death by overwork, known as karoshi, as they work more than 80 hours of overtime each month, according to a government survey.
8/19 Over-cooked potatoes and burnt toast ‘could cause cancer’
The Food Standards Agency (FSA) has issued a public warning over the risks of acrylamide - a chemical compound that forms in some foods when they are cooked at high temperatures (above 120C).
9/19 Cervical cancer screening attendance hits 19 year low
Cervical screening tests are a vital method of preventing cancer through the detection and treatment of abnormalities in the cervix, but new research shows that the number of women using this service has dropped to a 19 year low.
10/19 High blood pressure may protect over 80s from dementia
The ConversationIt is well known that high blood pressure is a risk factor for dementia, so the results of a new study from the University of California, Irvine, are quite surprising. The researchers found that people who developed high blood pressure between the ages of 80-89 are less likely to develop Alzheimer’s disease (the most common form of dementia) over the next three years than people of the same age with normal blood pressure.
11/19 Most child antidepressants are ineffective and can lead to suicidal thoughts
The majority of antidepressants are ineffective and may be unsafe, for children and teenager with major depression, experts have warned. In what is the most comprehensive comparison of 14 commonly prescribed antidepressant drugs to date, researchers found that only one brand was more effective at relieving symptoms of depression than a placebo. Another popular drug, venlafaxine, was shown increase the risk users engaging in suicidal thoughts and attempts at suicide
12/19 'Universal cancer vaccine’ breakthrough claimed by experts
Scientists have taken a “very positive step” towards creating a universal vaccine against cancer that makes the body’s immune system attack tumours as if they were a virus, experts have said. Writing in Nature, an international team of researchers described how they had taken pieces of cancer’s genetic RNA code, put them into tiny nanoparticles of fat and then injected the mixture into the bloodstreams of three patients in the advanced stages of the disease. The patients' immune systems responded by producing "killer" T-cells designed to attack cancer. The vaccine was also found to be effective in fighting “aggressively growing” tumours in mice, according to researchers, who were led by Professor Ugur Sahin from Johannes Gutenberg University in Germany
13/19 Green tea could be used to treat brain issues caused by Down’s Syndrome
A compound found in green tea could improve the cognitive abilities of those with Down’s syndrome, a team of scientists has discovered. Researchers found epigallocatechin gallate – which is especially present in green tea but can also be found in white and black teas – combined with cognitive stimulation, improved visual memory and led to more adaptive behaviour. Dr Rafael de la Torre, who led the year-long clinical trial along with Dr Mara Dierrssen, said: “The results suggest that individuals who received treatment with the green tea compound, together with the cognitive stimulation protocol, had better scores in their cognitive capacities”
14/19 Taking antidepressants in pregnancy ‘could double the risk of autism in toddlers’
Taking antidepressants during pregnancy could almost double the risk of a child being diagnosed with autism in the first years of life, a major study of nearly 150,000 pregnancies has suggested. Researchers have found a link between women in the later stages of pregnancy who were prescribed one of the most common types of antidepressant drugs, and autism diagnosed in children under seven years of age
15/19 Warning over Calpol
Parents have been warned that giving children paracetamol-based medicines such as Calpol and Disprol too often could lead to serious health issues later in life. Leading paediatrician and professor of general paediatrics at University College London, Alastair Sutcliffe, said parents were overusing paracetamol to treat mild fevers. As a result, the risk of developing asthma, as well as kidney, heart and liver damage is heightened
16/19 Connections between brain cells destroyed in early stages of Alzheimer’s disease
Scientists have pinpointed how connections in the brain are destroyed in the early stages of Alzheimer’s disease, in a study which it is hoped will help in the development of treatments for the debilitating condition. At the early stages of the development of Alzheimer’s disease the synapses – which connect the neurons in the brain – are destroyed, according to researchers at the University of New South Wales, Australia. The synapses are vital for brain function, particularly learning and forming memories
17/19 A prosthetic hand that lets people actually feel through
The technology lets paralysed people feel actual sensations when touching objects — including light taps on the mechanical finger — and could be a huge breakthrough for prosthetics, according to its makers. The tool was used to let a 28-year-old man who has been paralysed for more than a decade. While prosthetics have previously been able to be controlled directly from the brain, it is the first time that signals have been successfully sent the other way
18/19 Aspirin could help boost therapies that fight cancer
The latest therapies that fight cancer could work better when combined with aspirin, research has suggested. Scientists from the Francis Crick Institute in London say the anti-inflammatory pain killer suppresses a cancer molecule that allows tumours to evade the body’s immune defences. Laboratory tests have shown that skin, breast and bowel cancer cells often generate large amounts of this molecule, called prostaglandin E2 (PGE2). But Aspirin is one of a family of drugs that sends messages to the brain to block production of PGE2 and this means cancer cells can be attacked by the body’s natural defences
19/19 Potatoes reduce risk of stomach cancer
Scientists have found people who eat large amounts of white vegetables were a third less likely to contract stomach cancer. The study, undertaken by Chinese scientists at Zhejiang University, found eating cauliflower, potatoes and onions reduces the chance of contracting stomach cancer but that beer, spirits, salt and preserved foods increased a person’s risk of the cancer
Women with breast cancer and defective BRCA genes are also known to respond to olaparib.
The new findings are published in the New England Journal of Medicine.
Each year more than 41,700 men are diagnosed with prostate cancer in the UK and nearly 11,000 die from the disease.
In 84% of cases, patients live 10 or more years, but once the disease has spread and stopped responding to hormone treatments the chances of survival are much slimmer.
Dr Aine McCarthy, science information officer at Cancer Research UK, one of a number of organisations that contributed funding for the trial, said: "This trial is exciting because it could offer a new way to treat prostate cancer by targeting genetic mistakes in cancers that have spread.
"The hope is that this approach could help save many more lives in the future."
Dr Iain Frame, director of research at Prostate Cancer UK, which also provided funding, said: "Sometimes we find answers to research questions from unexpected sources.
"These results demonstrate just how much we can benefit from the success of treatments for other diseases and it's exactly the type of research we want to see more of.
"Although it's still early days, this drug has already been approved for use for other cancers, so it's more likely it will get into the hands of the men who need it more quickly if it's proven to be successful in further trials."
The research also received support from the Movember Foundation, which raises funds and cancer awareness by promoting the growth of moustaches.
Press AssociationReuse content